Organon (OGN)

Executive Summary

Organon & Co. is a global healthcare company spun off from Merck in 2021, specializing in women's health, biosimilars, and established therapeutic brands. With a portfolio of over 70 medicines reaching more than 140 markets, the company addresses critical healthcare needs across reproductive health, contraception, fertility, and menopause. Organon leverages deep commercial expertise and heritage brands to generate steady revenue, but faces challenges from generic competition and patent expirations on legacy products. The company is investing in geographic expansion, particularly in emerging markets, and advancing its biosimilar pipeline to offset revenue declines. Financially, Organon maintains a solid balance sheet with strong cash flow, supporting dividends and share repurchases. The women's health segment benefits from increasing awareness and demand for inclusive healthcare, while biosimilars gain traction due to cost pressures on healthcare systems. Organon's strategy focuses on targeted innovation, partnerships, and expanding access to improve health outcomes globally.

Upcoming Catalysts (preview)

• H2 2026FDA decision on biosimilar of Stelara (ustekinumab)70% success
• Q4 2026Launch of next-generation contraceptive or fertility product50% success
• TBDStrategic acquisition or partnership to bolster pipeline40% success